JP Morgan Maintains Overweight on Adarx Pharmaceuticals, Lowers Price Target to $36
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Tessa Romero maintains Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight and lowers the price target from $38 to $36.
JP Morgan analyst Tessa Romero maintains Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight and lowers the price target from $38 to $36.
